No­var­tis takes Gilenya fight to Supreme Court as gener­ic com­pe­ti­tion looms

No­var­tis stands to lose more than a quar­ter bil­lion dol­lars in sales this year if Gilenya gener­ics are al­lowed to mar­ket. So it’s tak­ing the fight all the way to the Supreme Court.

The Swiss phar­ma gi­ant an­nounced on Wednes­day that a US fed­er­al ap­peals court has re­fused to re­hear its Gilenya patent case against pri­vate Chi­nese biotech HEC Pharm. Next up? No­var­tis plans on pe­ti­tion­ing the Supreme Court to up­hold the va­lid­i­ty of its patent No. 9,187,405, re­ferred to in court doc­u­ments as the ‘405 patent, cov­er­ing a 0.5 mg dos­ing reg­i­men of the mul­ti­ple scle­ro­sis drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER